Classification of Brain Injury Pathophysiology With GFAP and UCH-L1

Running Title: Classifying Brain Injury With Serum Markers

Daniel Rafter MD [a,b], Zhuliu Li [c], Tory Schaaf PhD [a,b], Kristen Gault [a], Maxwell Thorpe [a], Shivani Venkatesh [a], Radhika Edpuganti [a], Rui Kuang PhD [a,c], Uzma Samadani MD [a,b,d]

Corresponding Author:
Uzma Samadani MD PhD, 1 Veterans Drive, Dept of Neurosurgery, Minneapolis, MN 55417
usamadan@umn.edu; 612 725 2000

Daniel Rafter MD, Danel.Rafter@centracare.com
Zhuliu Li, lixx3617@umn.edu
Tory Schaaf PhD, schaa033@umn.edu
Kristen Gault, kristen.gault81@gmail.com
Maxwell Thorpe, maxwell.thorpe7@gmail.com,
Radhika Edpuganti, edpug001@umn.edu,
Rui Kuang PhD, kuang@umn.edu,

____

[a] Department of Bioinformatics and Computational Biology, University of Minnesota, 111 South Broadway, Suite 300, Rochester, MN 55904 University of Minnesota

[b] Neurosurgery, Centracare, 1406 6th Ave N, St Cloud, MN 56303

[c] Department of Computer Science and Engineering, University of Minnesota; 100 Church St S.E., Minneapolis MN 55455

[d] Division of Neurosurgery, Minneapolis VA, 1 Veterans Drive, Minneapolis, MN 55417

Key words: anoxic injury, brain injury, diffuse axonal injury, spontaneous hemorrhage

____

Abstract: Brain injury is pathophysiologically diverse, with many cases presenting with mixed pathologies. Utilizing serum biomarkers to investigate the pathophysiology of injury would help to aid in understanding prognosis and targeting therapeutics. One goal of the study is to develop a traumatic brain injury classification scheme based on two serum biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal L1 (UCH-L1). GFAP and UCH-L1 serum marker analysis was performed on patients with isolated traumatic brain injury or healthy, uninjured controls within 32 hours of hospital admission. Machine learning was utilized for classification of brain injury and to develop a novel algorithm capable of classifying the type of brain injury based on GFAP and UCH-L1 concentrations. Each patient's brain injury was classified using standard clinical and radiographic assessments and stratified into one of four trauma groups: trauma, spontaneous hemorrhage, oxygen deprivation, or a high-velocity trauma with negative radiographic finding. Analysis of prospectively collected serum for GFAP and UCH-L1 was performed on 61 patients and 39 controls. The subjects with trauma, spontaneous hemorrhages and oxygen deprivation could be distinguished from controls with AUC = 1.00. Combination of GFAP and UCH-L1 concentrations distinguished the high-velocity injuries that were negative for radiographic indicators (CT-negative) from controls with AUC of 0.93. Serum biomarker profiles were found to accurately predict etiology across four distinct brain injuries, including CT-negative. Serum markers GFAP and UCHL1 may be helpful for classifying the nature of brain injury, which will aid with prognostication and development of therapeutics.

____

Introduction

The objective classification of brain injuries using markers for the heterogeneous pathophysiology indicative of different mechanistic forces of injury remains a challenge. Due to the heterogeneity of injury that occurs in conjunction with traumatic brain injury (TBI), accurate classification of injury is challenging. Serum biomarkers can be used as diagnostic tools that are reliable in their ability to classify injuries based on critical factors like mechanism of action.[1] Currently, the primary assessors used to classify brain injuries in an acute care setting are the patient's medical history, Glasgow Coma Scale (GCS), and computed tomography (CT).

However, these modalities alone fail to capture the full spectrum of injury. The diverse pathophysiologic mechanisms that contribute to neurological damage in brain injuries create a unique pattern which can be measured using serum based biomarkers to create specific injury profiles of traumatic and nontraumatic brain injuries. Glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase-L1 (UCH-L1) are serum based biomarkers with neurologic specificity.[1, 2] GFAP and UCH-L1 have the potential to improve classification of injury. These biomarkers are altered with mechanisms that contribute to neurological damage in brain injury. For example, cellular death such as axonal shearing and the immediate release of cellular contexts may potentially occur during a traumatic injury, in contrast to a delayed release of cellular contents seen in oxygen deprivation injuries; a result of slower apoptosis.[1, 3] This information is useful in predicting the most effective therapeutic interventions as well as patient response to said interventions.

GFAP is a protein found in astrocytes, enteric glial cells, and non-myelinating Schwann cells which is upregulated after injury to the central nervous system. Cellular release of the protein and its byproducts into serum occurs rapidly with levels detectable within 6 hours of injury and in a severity dependent dose, thus making them an important indicator for acute brain injury.[3, 4] In previous studies, elevated levels of GFAP have been detected within 6 hours of injury with a rapid decrease that is dependent on the type of injury as well as the severity of the damage.[4] Comparison of GFAP levels have identified differences in serum levels between patients with skull injuries versus those diagnosed with traumatic or nontraumatic intracerebral (ICH) hemorrhage. ICH produced significantly higher GFAP levels within the first 32 hours after injury than those diagnosed with cranial fractures absent of ICH. The highest levels of GFAP were found in individuals diagnosed with skull fractures combined with ICH.[4] Additional research suggests that serum GFAP concentrations are an ideal biomarker to differentiate between various nontraumatic brain injuries such as ICH and acute ischemic stroke (AIS) with higher GFAP elevations presenting in cases where damage was more extensive [3, 5-8]

Research on serum biomarkers has also shown that UCH-L1, an enzyme responsible for degradation in nerve cells, may also offer useful information in the classification and severity of brain injuries and has been associated with poor outcomes in individuals with both traumatic and nontraumatic brain injuries.[9] UCH-L1 is hypothesized to play a role in axon and neuronal repair by removing abnormal proteins that are present after injury.[10] Exploratory studies investigating targeted serum biomarkers >32 hours post injury in adults and children with mild to severe TBI have found significant increases in serum UCH-L1 with increased levels directly correlated with the severity of injury. [10-12] Further examination of pediatric patients determined that UCH-L1

accurately detects acute intracranial lesions and may be useful in differentiating various

pathologies associated with injury.[12] UCH-L1 concentrations were also increased in patients

diagnosed with skull fractures and in patients with a CT negative brain injury, thus highlighting

its value as a diagnostic tool when compared with neuroimaging in diagnosing and

characterization of small lesions and minor pathophysiological abnormalities.[12] UCH-L1

elevation has also been noted in trauma patients suffering from body trauma, and its release has a

similar pattern to release after head trauma and is thought to be a result of UCH-L1 having the

ability to be ultrasensitive to the slightest neuronal disruptions that could occur during any sort of

impact to the body.[13, 14] The distinct features and origins of UCH-L1 are important because they

provide a means to distinguish and assess cell specific injury patterns as well as the various types

of pathology associated with brain injuries.[15]

The objective of the current study was to examine UCH-L1 and GFAP concentrations in the

acute period of <32 hours of injury in order to differentiate between the following five groups:

healthy controls, CT negative TBI with high-velocity trauma (CTN-HVT), oxygen deprivation

injuries from cardiac or respiratory arrest (CA/RA), spontaneous hemorrhage, and traumatic

hemorrhage. We hypothesized that each group would have a different biomarker profile because

the mechanisms and magnitude in which these biomarkers are released will vary across groups.

Successful identification of the differences in these groups will allow for a rapid, accurate

diagnosis that will optimize triage and treatment times as well as minimizing the need for

unnecessary medical procedures and potentially improve long term patient outcome.

Materials and Methods

Participants included trauma patients of all ages presenting to a single hospital Emergency Department (ED), trauma bay, or as direct transfer to neurosurgery. Patients were excluded if they had a major psychiatric or neurological disorder, developmentally abnormal, or were prisoners. At the time of admission, potential participants underwent screening before providing informed consent. This screening process is necessary, because many of the patients admitted with trauma were in need of time-sensitive care that would become compromised by the time it takes to obtain informed consent for this minimal risk study. Informed consent was obtained upon completion of the screening process as soon as it became appropriate due to either (1) available time, (2) recovery of cognitive competence, or (3) the presence of a legal proxy. In the case that a potential participant died before informed consent was obtained, and no legal proxy was determined, consent to participate in the study was waived. These procedures have been assessed by the appropriate review committee. Patient information was identified by searching EPIC medical records for all trauma admissions and cross-checking with the American College of Surgeons trauma registry utilized in the hospital. Clinical diagnosis and assignment to brain injury groups was performed by trained clinicians, based on clinical findings.

Blood collection was obtained at the time of admission for clinical purposes, and additional specimen were obtained and retained for research purposes. This study focused on a subset of blood draws taken as part of the CLASSIFY clinical trial. Patients had up to three blood draws taken within 32 hours of hospital admission. Study participants contributed at least one and up to three blood draws with target times of 0 (as close to ictus as feasible), 3, and 24 hours. GFAP and UCHL1 concentrations from all available time points were matched and utilized for data

analysis. The blood was drawn through venipuncture or via a central venous access if one was required by the standard of care. Blood draws were taken within 32 hours of presentation to the hospital. UCH-L1 and GFAP serum concentrations were measured using an i-STAT system (Abbott).

Analysis and plotting were performed using MATLAB (R2018b). Only samples with both valid UCH-L1 and GFAP biomarker results were included in the analysis. Biomarker levels below the detectable limit prior to transformation were assigned a value of zero, but included in the analysis. Biomarker levels above the detectable limit (50,000 pg/ml for GFAP and 20,000 pg/ml for UCH-L1) were included in analysis as equal to the upper limit.

Differences in mean and median raw concentrations between Trauma, SpontHem, CA/RA, CTN-HVT and Control groups at all timepoints measured within 32 hours were assessed using the t-test and Wilcoxon rank-sum test. Concentrations were log-transformed to achieve normality prior to the plotting and data analyses.

Machine Learning

Support Vector Machine (SVM)[16] was utilized for the classification of the patient samples in our prediction tasks. Among the supervised learning methods, SVM generalizes well on new test data, and the decision function of SVM is simply defined by a subset of training samples without requiring training with big data.

Support vector machine and kernels:

Given a set of training data $\{(\mathbf{x}_i, y_i)\}_{i=1}^{N}$ with $\mathbf{x}_i$ be the i-th sample vector and $y_i \in \{+1, -1\}$ as its label, the SVM outputs the score $f(\mathbf{x}_{new})$ of a new sample $\mathbf{x}_{new}$ as

$$f(\mathbf{x}_{\text{new}}) = \sum_{i=1}^{N} \alpha_i y_i K(\mathbf{x}_i, \mathbf{x}_{\text{new}}) + b,$$

where $K(\mathbf{x}_i, \mathbf{x}_j)$ is the kernel function defined with a mapping of the original feature space into a transformed space for non-linear classification. We use the Gaussian kernel defined below as the non-linear kernel function:

$$K(\mathbf{x}_i, \mathbf{x}_j) = \exp(-\frac{\|\mathbf{x}_i - \mathbf{x}_j\|^2}{\sigma^2})$$

The α_i for $i = 1, \ldots, N$ are obtained by solving the optimization problem

$$\text{subject to } \sum_{i=1}^{N} \alpha_i y_i = 0, \text{ and } 0 \le \alpha_i \le \frac{1}{2N\lambda}, \forall i = 1, \ldots, N,$$

$$\underset{\alpha_1, \ldots, \alpha_N}{\text{maximize}} \sum_i \alpha_i - \frac{1}{2} \sum_{i,j=1}^{N} \alpha_i \alpha_j y_i y_j K(\mathbf{x}_i, \mathbf{x}_j)$$

where λ is a hyper-parameter.

$$b = -0.5 * (\max_{j:y_j=-1} \sum_{i=1}^{N} \alpha_i y_i K(\mathbf{x}_i, \mathbf{x}_j) + \min_{j:y_j=1} \sum_{i=1}^{N} \alpha_i y_i K(\mathbf{x}_i, \mathbf{x}_j)).$$

After obtaining all the α_is, the scalar b is obtained as:

We performed leave-one-out cross-validation to evaluate the prediction performance of SVM. In the evaluation, we hold out one sample at a time as the test data and treat the rest samples as training data to obtain the SVM model for classifying the held-out sample in the test data. We repeat the procedure on every sample and report the overall test accuracy in Table 4.

The parameters σ and $\frac{1}{2N\lambda}$ are chosen from {0·1, 0·5, 1, 5, 10} by grid searching.

We measured the classification accuracy using the Area Under the ROC Curve (AUC)[17] denoting the number of true positives, true negatives, false positives and false negatives as TP, TN, FP, and FN respectively, the true positive rate (TPR) and false positive rate (FPR) are defined as

$$TPR = \frac{TP}{TP+FN}, \quad FPR = \frac{FP}{FP+TN}$$

Area Under the ROC Curve (AUROC) measures the area under the receiver operating characteristic (ROC) curve which plots the true positive rate (TPR) and false positive rate (FPR) at different classification thresholds. Thus, the AUC represents the probability that a randomly chosen positive sample receives a higher score than a randomly chosen negative sample.

Results

100 matched GFAP and UCH-L1 samples were analyzed, 35 within the Trauma group, 10 within the spontaneous hemorrhage (SpontHem) group, 6 within the oxygen deprivation due to cardiac arrest or respiratory arrest (CA/RA) group, 10 within the computed tomography negative -high velocity trauma (CTN-HVT) group, and 39 within the control group (table 1). Log-transformation was performed on the concentrations of GFAP and UCH-L1 before conducting data analyses. Data collection was continuous except for the exclusion of one patient, who sustained a cardiac arrest resulting in a high speed collision and thus had a high velocity trauma confounded with an anoxic injury.

We first explored whether a single biomarker can separate the five different groups. The boxplot for each of the five groups (Figure 1). We observed a larger range in GFAP concentrations compared to UCH-L1. We performed one-way ANOVA analysis to test the null hypothesis that the mean is the same for all the five groups based on the GFAP and UCH-L1 concentrations, respectively. Next, we performed t-test and Wilcoxon rank-sum test on each of the ten combinations of the five groups to test whether using a single marker can distinguish each pair of groups. The p-values are shown in Table 2 and Table 3. Comparing with the controls, every one of the four subject groups has significantly different means ($p < 0.01$; t-test) and medians ($p < 0.01$; rank-sum test) on either GFAP or UCH-L1 concentrations; all the pairs of the subject groups but the CA/RA vs CTN-HVT have significantly different means ($p < 0.01$; t-test) and medians ($p < 0.01$; rank-sum test) on the GFAP concentrations; SpontHem vs CA/RA and CA/RA vs CTN-HVT have significantly different means ($p < 0.01$; t-test) and medians ($p < 0.01$; rank-sum test) on UCH-L1.

We observed that samples in CTN-HVT can be distinguished from controls using either GFAP or UCH-L1. We performed t-test and Wilcoxon rank-sum tests to test how significant the difference on each single biomarker is between the two groups. The small p values shown in Tables 2 and 3 suggest the samples of CTN-HVT have significantly different means (t test: p = 8·04E-08/7·80E-06 for GFAP/UCH-L1) and medians (rank-sum test: for GFAP/UCH-L1 p = 3·76E-06/9·17E-05) .

Next, we explored whether the GFAP and UCH-L1 concentrations can be combined as predictors to classify the samples in each pair of the five different groups using machine learning with the Support Vector Machine (SVM). The concentrations of GFAP and UCH-L1 for each patient sample within the four subject groups and controls were plotted (Figure 2). We measured the classification accuracy with the Area Under the ROC Curve (AUC) scores which are shown in Table 4. One can observe that the subjects with trauma, SpontHem and CR/RA could be distinguished from controls with AUC = 1·00. In the comparisons within the four subject groups, the AUC is 1·00 for the SpontHem VS CA/RA and SpontHem VS CTN-HVT; The AUC scores for the remaining pairs of subject groups except Trauma VS SpontHem are all larger than 0·95. The high AUC of 0·93 suggest that the biomarkers GFAP and UCH-L1 can jointly distinguish the CTN-HVT samples from controls. These results suggest that the biomarkers GFAP and UCH-L1 can jointly distinguish the patients from different groups.

Discussion

We evaluated serum biomarker concentrations of ubiquitin c-terminal hydrolase-L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in the acute period of traumatic brain injury (<32 hours of injury) to differentiate between five different groups of patients: uninjured control, CT-negative TBI with high-velocity trauma (inertial injury), oxygen deprivation injury (CA/RA), spontaneous hemorrhage (non traumatic injury) and traumatic hemorrhage. Rapid evaluation of two serum biomarkers was able to differentiate between traumatic injuries and nontraumatic injuries, due to a range of causes. Biomarker profiles differ amongst the groups because the mechanisms through which the biomarkers are being released and to what magnitude varies. Oxygen deprivation led to the highest concentrations of UCH-L1 across all types of TBIs examined and had lower levels of GFAP compared to the trauma and spontaneous hemorrhage groups. UCH-L1 activity protects neurons from hypoxic injury. Ischemic events produce reactive lipids such as cyclopentenone prostaglandins and over time these inhibit UCH-L1's function to remove damaged proteins. Recent evidence shows a single point mutation inhibits lipid binding and ameliorated cell death and neurite injury.[10] Our results depict a differential profile of GFAP and UCH-L1 for ischemic events which could be useful for stratifying patients for the development of drugs targeting the lipid binding interface of UCH-L1.

GFAP and UCH-L1 serum levels measured immediately after a traumatic hemorrhage injury correlated with increased likelihood of poor outcomes six months post injury. Previously, GFAP alone was able to accurately predict traumatic hemorrhage and no improvement was found by adding UCH-L1 concentrations.[18] GFAP and UCHL-1 concentrations were also assessed in

patients with mild TBI. These biomarkers were increased in patients with unfavorable short-term outcomes. These levels were significant within 6 hours post injury.[19]

Concentrations of GFAP were more elevated for spontaneous hemorrhage as compared to hemorrhages caused by trauma. Conversely, UCH-L1 concentrations were modestly increased for trauma-induced bleeds in comparison to spontaneously presenting hemorrhages. Increased GFAP concentrations may also be due to larger volumes of blood found in spontaneous hemorrhages. Patients who experience multiple TBIs may potentially develop autoantibodies against GFAP that may cause reduced levels of GFAP with subsequent injuries. [20] Thus we would caution against use of a single marker in classifying injury.

Consistent with previous studies, we were able to accurately predict an ischemic stroke from hemorrhagic stroke, where immediate cell death results in a rise in GFAP concentration in individuals who experienced an hemorrhagic stroke.[6] GFAP levels from ischemic patients were still significantly elevated compared to healthy controls. However, we found robust serum levels of UCH-L1 from ischemic injury, enabling better classification, when both biomarkers are combined. We demonstrate improved predictive potential using both UCH-L1 and GFAP as shown in Figure 2 with AUC of 0·93. The AUC values suggest a reasonable model to classify brain injury.

In this study, we focused on a blood draws taken within 32 hours of presentation to the emergency department. Both biomarkers are known to have different kinetic properties due to their location and release within the body. UCH-L1 peaks early and decreases rapidly in

intracranial lesions, GFAP increases after 4 hours and declines at 16 hours .[13] Previously, GFAP and UCH-L1 concentrations acquired within 48 hours post injury were capable of distinguishing mass lesions from diffuse injuries. Analysis of concentrations up to seven days post injury did not increase predictive power to differentiate between injury type.[21] A major challenge for diagnosing traumatic brain injuries is that patients can present with a wide range of symptoms or be unconscious. Furthermore, some symptoms can be milder and harder to differentiate from other disorders, leading patients to delay presentation to the emergency department until they experience more severe symptoms. We found these two biomarkers to be accurate in diagnosis of injuries of different etiology and with little dependence on the timing of the blood draw when taken within 32 hours of presentation to the emergency department. GFAP and UCH-L1 blood serum markers may also be useful for detecting the long lasting neurological damage found in some COVID-19 patients.[8]

The findings of this study demonstrate the utility of using the two serum biomarkers GFAP and UCH-L1 for classification of diverse TBIs. This study is limited to small sample sizes for each type of pathology and necessitates investigation of larger sample sizes to overcome potential sampling bias. Further, the predictive power of the biomarkers was only assessed by acute clinical outcomes from known etiologies. We envision performing a large-scale study assessing these two biomarkers in conjunction with others to classify the nature of injury, with the overall goal of predicting patient outcomes. Information from these studies may also elucidate biological differences in race and gender that are known to exist across the spectrum of TBIs. These diagnostic tools will improve the quality of life for patients, give guidance to families of the injured, and create objective measures for physicians.

Author Confirmation Statement

US conceived and designed the study. ZL, DR and RK were responsible for data analysis. MT, SV, and RE were responsible for data collection. DR, TS, ZL, RK, and US were responsible for data interpretation.

____

Funding Statement

Dr. Samadani reports grants from Abbott Diagnostic Laboratories, grants from Minnesota State Office of Higher Education, during the conduct of the study; personal fees from Abbott Diagnostic Laboratories, personal fees from The American Association of Neuroscience Nurses, personal fees from Cottage Health, personal fees from Google Inc., personal fees from Integra Corp, personal fees from Medtronic Corp, personal fees from National Neurotrauma Society, personal fees from Minnesota, Texas, Louisiana and Wisconsin Coaches Associations, personal fees from National Football League and USA Football, other from National Football League, other from Oculogica Inc., other from Veterans Administration, outside the submitted work .

References

1.   McMahon, P., Panczykowski D., Yue J., Puccio A., Inoue T., Sorani M., Lingsma H., Maas A., Valadka A., Yuh E., Mukherjee P., Manley G., Okonkwo D., and TRACK-TBI Investigators. (2015). Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J Neurotrauma 32, 527-33.

2.   Gan Z, Stein S, Swanson R, Guan S, Garcia L, Mehta D, and Smith D. (2019). Blood Biomarkers for Traumatic Brain Injury: A Quantitative Assessment of Diagnostic and Prognostic Accuracy. Front Neurol. 10, 446.

3.   Agoston D, Shutes-David A, and Peskind E. (2017). Biofluid biomarkers of traumatic brain injury. Brain Inj. 31, 1195-203.

4.   Aydin I, Algin A, Poyraz MK, and Yumrutas O. (2018). Diagnostic value of serum glial fibrillary acidic protein and S100B serum levels in emergency medicine patients with traumatic versus nontraumatic intracerebral hemorrhage. Niger J Clin Pract. 21, 1645-50.

5.   Puspitasari V, Gunawan P, Wiradarma H, and Hartoyo V. (2019). Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke. Open Access Maced J Med Sci. 7, 1471-4.

6.   Luger S, Witsch J, Dietz A, Hamann GF, Minnerup J, Schneider H, Sitzer M, Wartenberg K, Niessner M, Foerch C, BE FAST II, and the IGNITE Study Groups. (2017). Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke. Clin Chem. 63, 377-85.

7.   Katsanos AH, Makris K, Stefani D, Koniari K, Gialouri E, Lelekis M, Chondrogianni M, Zompola C, Dardiotis E, Rizos I, Parissis J, Boutati E, Voumvourakis K, and Tsivgoulis G. (2017). Plasma Glial Fibrillary Acidic Protein in the Differential Diagnosis of Intracerebral Hemorrhage. Stroke 48, 2586-8.

8.   DeKosky S, Kochanek P, Valadka A, Clark R, Chou S, Au A, Horvat C, Jha R, Mannix R, Wisniewski S, Wintermark M, Rowell S, Welch R, Lewis L, House S, Tanzi R, Smith D, Vittor A, Denslow N, Davis M, Glushakova O, and Hayes R. (2020). Blood Biomarkers for Detection of Brain Injury in COVID-19 Patients. J Neurotrauma. Online ahead of print.

9.   Berger, R., Hayes, R., Richichi, R., Beers S., and Wang K. (2012). Serum concentrations of ubiquitin C-terminal hydrolase-L1 and alphaII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI. J Neurotrauma 29, 162-167.

10.   Osier N., Conley Y., Okonkwo D., and Puccio A. (2018). Variation in Candidate Traumatic Brain Injury Biomarker Genes Are Associated with Gross Neurological Outcomes after Severe Traumatic Brain Injury. J Neurotrauma 35, 2684-90.

11.   Liu H., Povysheva N., Rose M., Mi Z., Banton J., Li W., Chen F., Reay D., Barrionuevo, G. Zhang, F., and Graham S. (2019). Role of UCHL1 in axonal injury and functional recovery after cerebral ischemia. Proc Natl Acad Sci U S A. 116, 4643-50.

12.   Mondello S, Kobeissy F, Vestri A, Hayes R, Kochanek P, and Berger R. (2016). Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury. Sci Rep. 6, 28203.

13.   Papa L., Brophy G., Welch R., Lewis L., Braga C., Tan C., Ameli N., Lopez M., Haeussler C., Mendez Giordano D., Silvestri S., Giordano P, Weber K., Hill-Pryor C., Hack D. (2016). Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP

and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury. JAMA Neurol. 73, 551-60.

14.   Papa L., Zonfrillo M., Welch R., Lewis L., Braga C., Tan C., Ameli N., Lopez M., Haeussler C., Giordano D., Giordano P., Ramirez J., and Mittal M. (2019). Evaluating glial and neuronal blood biomarkers GFAP and UCH-L1 as gradients of brain injury in concussive, subconcussive and non-concussive trauma: a prospective cohort study. BMJ Paediatr Open. 3, e000473.

15.   Ren C, Kobeissy F, Alawieh A, Li N, Zibara K, Zoltewicz S, Guingab-Cagmat J., Larner S., Ding Y., Hayes R., Ji X., and Mondello S. (2016). Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients. Sci Rep. 6, 24588.

16.   Corinna Cortes V. (1995). Support-vector networks. Machine Learning 20, 273-97.

17.   Fawcett, T. (2006). An introduction to ROC analysis. Pattern Recognition Letters 27, 861-74.

18.   Anderson T., Hwang J., Munar M., Papa L., Hinson H., Vaughan A., and Rowell S. (2020). Blood-based biomarkers for prediction of intracranial hemorrhage and outcome in patients with moderate or severe traumatic brain injury. J Trauma Acute Care Surg. 89, 80-6.

19.   Lewis L., Papa L., Bazarian J., Weber A., Howard R., and Welch R. (2020). Biomarkers May Predict Unfavorable Neurological Outcome after Mild Traumatic Brain Injury. J Neurotrauma 37, 2624-2631

20.   Zhang J., Zhang C., Lin X., Zhang Q., Wang J., and Shi S. (2013). Serum glial fibrillary acidic protein as a biomarker for differentiating intracerebral hemorrhage and ischemic stroke in patients with symptoms of acute stroke: a systematic review and meta-analysis. Neurol Sci. 34, 1887-92.

21.   Posti J., Takala R., Runtti H., Newcombe V., Outtrim J., Katila A., Frantzén J., Ala-Seppälä H., Coles J., Hossain M., Kyllönen A., Maanpää H., Tallus J., Hutchinson P., Gils M., Menon D., and Tenovuo O. (2016). The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 During the First Week After a Traumatic Brain Injury: Correlations With Clinical and Imaging Findings. Neurosurgery 79, 456-64.

22 (Table 1 reference). Teasdale G, Jennett B. (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet 2, 81-4.

Classification of Brain Injury Pathophysiology With GFAP and UCHL-1

Running Title: Classifying Brain Injury With Serum Markers

Daniel Rafter MD [a,b], Zhuliu Li [c], Tory Schaaf PhD [a,b], Kristen Gault [a], Maxwell Thorpe [a], Shivani Venkatesh [a], Radhika Edgupanti [a], Rui Kuang PhD [a,c], Uzma Samadani MD [a,b,d]

Tables:

Table 1: Study demographics of patient groups stratified by injury type

Characteristic	Total	Traumatic Hemorrhage	CT (-) High Velocity Trauma	Spontaneous Hemorrhage	Cardiac/ Respiratory Arrest	Healthy Control
Subjects (n)	100	35	10	10	6	39
Age in years (range, mean)	16-87, 46·5	22-85, 53·3	17-77, 42·7	45-80, 59·9	27-87, 51·5	16-65, 37·1
Sex						
Female	45 (45%)	9 (26%)	2 (20%)	3 (30%)	2 (33%)	29 (74%)
Male	55 (55%)	26 (74%)	8 (80%)	7 (70%)	4 (67%)	10 (26%)
Race						
African American	22 (22%)	-	2 (20%)	3 (30%)	1 (17%)	16 (41%)
Asian	1 (1%)	-	1 (10%)	-	-	-
Caucasian	61 (61%)	28 (80%)	7 (70%)	5 (50%)	4 (67%)	17 (44%)
Hispanic or Latino	7 (7%)	2 (6%)	-	1 (10%)	-	4 (10%)
Mixed Race	1 (1%)	-	-	-	-	1 (3%)
Native American	3 (3%)	2 (6%)	-	-	1 (17%)	-
Unknown	5 (5%)	3 (9%)	-	1 (10%)	-	1 (3%)
Mechanism of Injury						
Assault	6 (6%)	2 (6%)	4 (40%)	-	-	-
Bicyclist Hit by Vehicle	7 (7%)	3 (11%)	4 (40%)	-	-	-
Incidental Fall	17 (17%)	17 (47%)	-	-	-	-

Motor Vehicle Crash	10 (10%)	8 (22%)	2 (20%)	-	-	-
Pedestrian Struck by Vehicle	1 (1%)	1 (3%)	-	-	-	-
Other	20 (20%)	4 (11%)	-	10 (100%)	6 (100%)	-
None	39 (38%)	-	-	-	-	39 (100%)
GCS on Arrival						
13 – 15	69 (69%)	17 (48%)	10 (100%)	3 (30%)	-	39 (100%)
8 – 12	3 (3%)	3 (9%)	-	-	-	-
7 or less	28 (28%)	15 (43%)	-	7 (70%)	6 (100%)	-
Loss of Consciousness Duration						
0-30 mins	10 (10%)	8 (23%)	2 (20%)	-	-	-
30 mins – 24 hrs	7 (7%)	7 (20%)	-	-	-	-
Greater than 24 hrs	5 (5%)	1 (3%)	-	3 (30%)	1 (17%)	-
None	52 (52%)	5 (14%)	5 (50%)	3 (30%)	-	39 (100%)
Unknown	26 (26%)	14 (40%)	3 (30%)	4 (40%)	5 (84%)	-

*GCS: Glasgow Coma Scale[20]

Table 2. Comparison between types of injury: p-values of t-test (GFAP/UCH-L1)

	SpontHem	CA/RA	CTN-HVT	Control
Trauma	3·98E-03/2·96E-02	4·80E-06/4·35E-05	7·53E-12/5·44E-04	1·05E-30/2·21E-16
SpontHem		1·40E-06/1·25E-07	5·64E-12/1·29E-01	4·05E-26/5·49E-09
CA/RA			1·04E-01/1·15E-09	1·01E-07/2·55E-22
CTN-HVT				8·04E-08/7·80E-06

Table 3. Comparison between types of injury: p-values of Wilcoxon rank-sum test (GFAP/UCH-L1)

	SpontHem	CA/RA	CTN-HVT	Control
Trauma	2·88E-03/2·16E-02	2·57E-05/6·97E-05	2·81E-09/4·09E-04	4·92E-17/2·45E-13
SpontHem		1·14E-04/9·61E-06	4·79E-07/1.17E-01	1·77E-09/1·90E-06
CA/RA			3·51E-01/5·48E-06	6·58E-07/3·85E-08
CTN-HVT				3·76E-06/9·17E-05

Table 4. Classification with SVM based on the combinations of UCH-L1&GFAP [AUC]

	SpontHem	CA/RA	CTN-HVT	Control
Trauma	0·83	0·95	0·97	1·00
SpontHem		1·00	1·00	1·00
CA/RA			0·98	1·00
CTN-HVT				0·93